A US-based study found Hispanic individuals had significantly higher metabolic dysfunction-associated steatotic liver disease prevalence at 47.0% compared to 40.7% in non-Hispanic whites, despite nearly half of all U.S. adults showing signs of fatty liver disease.
Trial reveals kimchi's dual action: consuming 3000 mg daily not only reduced body fat mass but also increased beneficial gut bacteria A. muciniphila while decreasing obesity-associated microbes.
New data from 227,866 patients shows semaglutide associated with 36% reduced risk of alcohol-related hospitalizations versus traditional AUD medications' modest 2% reduction.